Bifeprunox
Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =
| _has_physiological_data= | _has_gene_therapy=
| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=242332O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC51S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)CYGODHVAJQTCBG-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data= none | _legal_data=
| _other_data=7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
| _image_0_or_2 = Bifeprunox.png | _image_LR =
| _datapage = Bifeprunox (data page) | _vaccine_target=_type_not_vaccine | _legal_all= | _ATC_prefix_supplemental=none | _has_EMA_link = | CAS_number=350992-10-8 | PubChem=208951 | ChemSpiderID=181044 | ChEBI= | ChEMBL=218166 | DrugBank= | KEGG= | _hasInChI_or_Key=yes | UNII=AP69E83Z79 | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =
| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields= |verifiedrevid=459978705}} Bifeprunox (INN; code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]
In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3] An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]
Pharmacodynamics
Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.
See also
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
- ↑ Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Template:Webarchive Lundbeck Press Release.
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox".
Template:Dopaminergics Template:Serotonergics Template:Piperazines